EYPT · Insider Trading
EyePoint, Inc. Common Stock
Every open-market purchase and sale reported by EYPT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-24 | George Elston | Chief Financial Officer | MIXED | — | — |
| 2026-08-18 | Karen L. Zaderej | Director | Buy | +10,600 | +$52.26K |
| 2026-07-14 | Jay S. Duker | President and CEO | MIXED | +8,608 | −$118.63K |
| 2026-07-02 | Ramiro Ribeiro | Chief Medical Officer | MIXED | — | −$32.90K |
| 2026-05-27 | George Elston | Chief Financial Officer | MIXED | +3,873 | −$46.90K |
| 2026-04-20 | Ramiro Ribeiro | Chief Medical Officer | MIXED | — | −$16.43K |
| 2026-03-24 | Jay S. Duker | President and CEO | J | — | — |
| 2026-03-16 | Jay S. Duker | President and CEO | Buy | +1,500 | +$19.72K |
| 2026-03-06 | George Elston | Chief Financial Officer | G | — | — |
| 2026-03-05 | Ramiro Ribeiro | Chief Medical Officer | MIXED | — | −$23.43K |
| 2026-02-18 | Ramiro Ribeiro | Chief Medical Officer | MIXED | — | −$16.43K |
| 2026-01-07 | Nancy Lurker | Director | M | +75,133 | — |
| 2026-01-07 | Jay S. Duker | President and CEO | MIXED | +10,739 | −$169.51K |
| 2026-01-07 | George Elston | Chief Financial Officer | MIXED | +10,798 | −$75.65K |
| 2026-01-07 | Ramiro Ribeiro | Chief Medical Officer | MIXED | −13,294 | −$485.71K |
| 2026-01-06 | John B. Landis | Director | A | +40,000 deriv. | — |
| 2026-01-06 | Reginald J. Sanders | Director | A | +40,000 deriv. | — |
| 2026-01-06 | Fred Hassan | Director | A | +40,000 deriv. | — |
| 2026-01-06 | Goran Ando | Director | A | +41,500 deriv. | — |
| 2026-01-06 | Wendy F Dicicco | Director | A | +40,000 deriv. | — |
| 2026-01-06 | Nancy Lurker | Director | M | +12,666 | — |
| 2026-01-06 | Stuart Duty | Director | A | +40,000 deriv. | — |
| 2026-01-06 | Ramiro Ribeiro | Chief Medical Officer | MIXED | +13,294 | −$111.40K |
| 2026-01-06 | Jay S. Duker | President and CEO | MIXED | +57,048 | −$662.68K |
| 2026-01-06 | Karen L. Zaderej | Director | A | +40,000 deriv. | — |
| 2026-01-06 | George Elston | Chief Financial Officer | MIXED | +23,940 | −$187.29K |
| 2025-12-23 | George Elston | Chief Financial Officer | G | — | — |
| 2025-12-08 | Bihua Chen | — | Sell | −180,000 | −$2.83M |
| 2025-12-05 | Nancy Lurker | Director | Sell | −9,300 | −$140.48K |
| 2025-12-01 | Nancy Lurker | Director | Sell | −700 | −$10.46K |
| 2025-11-12 | Ramiro Ribeiro | Chief Medical Officer | Sell | −2,722 | −$31.60K |
| 2025-09-22 | George Elston | Chief Financial Officer | G | — | — |
| 2025-07-11 | Karen L. Zaderej | Director | M | +2,000 | — |
| 2025-07-11 | Jay S. Duker | President and CEO | MIXED | +8,979 | −$85.03K |
| 2025-07-11 | Nancy Lurker | Director | M | +11,111 | — |
| 2025-07-02 | Nancy Lurker | Director | G | — | — |
| 2025-06-25 | Jay S. Duker | President and CEO | J | −56,665 | −$465.22K |
| 2025-05-27 | George Elston | Chief Financial Officer | MIXED | +5,298 | −$12.51K |
| 2025-05-19 | Karen L. Zaderej | Director | Buy | +10,000 | +$59.00K |
| 2025-05-15 | Karen L. Zaderej | Director | Buy | +10,000 | +$54.45K |
| 2025-03-20 | Jay S. Duker | President and CEO | J | −20,000 | −$123.10K |
| 2025-02-11 | Jay S. Duker | President and CEO | MIXED | +4,945 | −$13.35K |
| 2025-02-11 | George Elston | Chief Financial Officer | M | +5,834 | — |
| 2025-02-11 | Nancy Lurker | Director | M | +20,000 | — |
| 2025-01-08 | Reginald J. Sanders | Director | A | +80,000 deriv. | — |
| 2025-01-07 | Goran Ando | Director | A | +41,500 deriv. | — |
| 2025-01-07 | Stuart Duty | Director | A | +40,000 deriv. | — |
| 2025-01-07 | Wendy F Dicicco | Director | A | +40,000 deriv. | — |
| 2025-01-07 | George Elston | Chief Financial Officer | MIXED | +20,210 | −$85.24K |
| 2025-01-07 | Jay S. Duker | President and CEO | MIXED | +34,679 | −$135.68K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Bihua Chen | 10%+ Owner | 8,265,000 | $3.52M |
| Nancy Lurker | Director | 421,235 | $179.64K |
| Jay S. Duker | President and CEO | 195,084 | $83.19K |
| George Elston | Chief Financial Officer | 121,691 | $51.90K |
| Karen L. Zaderej | Director | 49,100 | $20.94K |
| John B. Landis | Director | 21,400 | $9.13K |
| Goran Ando | Director | 13,150 | $5.61K |
| Wendy F Dicicco | Director | 9,967 | $4.25K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the EYPT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.